

# Personality and Total Health (PATH) Through Life (60s cohort)

<https://neurodegenerationresearch.eu/survey/personality-and-total-health-path-through-life-60s-cohort/>

## **Title of cohort**

Personality and Total Health (PATH) Through Life (60s cohort)

## **Acronym for cohort**

PATH 60s

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Kaarin

## **Name of Principal Investigator - Last name**

Anstey

## **Address of institution -Institution**

The Australian National University, Centre for Research on Ageing, Health and Wellbeing

## **Address of institution - Street address**

Florey Building, 54 Mills Rd, ACTON

## **Address of institution - City**

Canberra

## **Address of institution - Postcode**

2601

## **Country**

Australia

## **Website**

<http://crahw.anu.edu.au/research/projects/personality-total-health-path-through-life>

## **Contact email**

[Kaarin.Anstey@anu.edu.au](mailto:Kaarin.Anstey@anu.edu.au) or [path@anu.edu.au](mailto:path@anu.edu.au)

## **Funding source**

National Health and Medical Research Council

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Neurodegenerative disease in general

**Q1b. When are studies on the above condition(s) expected to become possible?**

Already possible

**Q2a. In a single sentence what is the stated aim of the cohort?**

To track and define the course of depression, anxiety, substance use and cognitive ability, identify environmental risk and protective factors within these domains, and examine the relationships between depression, anxiety and substance use with cognitive

**Q2b. What distinguishes this cohort from other population cohorts?**

Narrow age cohort followed up over a long amount of time with data enhanced by substudies including physical and genetic testing and neuroimaging

**Q3a. i) Number of publications that involve use of your cohort to date**

**Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

**Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

<http://crahw.anu.edu.au/research/projects/personality-total-health-path-through-life/published-papers>

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years**  
**From:**

60

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

64

**Q4b. Study criteria: what are the inclusion criteria?**

Registered on the Australian Electoral Roll in the ACT or Queanbeyan (NSW) and aged between 40-44 years at recruitment

**Q4c. Study criteria: what are the exclusion criteria?**

Out of age range for this cohort (<60 & >64)

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

1,000-5,000 participants

**Q6a. Please describe what measures are used to characterise participants**

Demographics, lifestyle, mental health and psychological scales, cognitive and physical tests

**Q6b. Are there additional measures for participants with a clinical disorder?**

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

No

If yes please specify

**Q7. What is the study design (select all that apply)?**

Longitudinal| Prospective cohort

**Q8. Are your cases matched by**

Age

**Q9a. Does your study include a specialised subset of control participants?**

No

**Q9b. If your study includes a specialised subset of control participants please describe**

**Q10a. i) Please enter the data collection start date**

01/01/2000

**Q10a. ii) Please enter the data collection end date**

01/01/2020

**Q10a. iii) Is data collection for this study**

Data collection ongoing| Data analysis ongoing

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

**Q11. Is data collected**

**Other please specify here**

**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

Yes (participants given permission to be re-contacted via PIs)

**Q13a. Please give information on the format and availability of data stored in a database (1)**

Data summarised in database

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (2)**

No

**% available**

**Q13a. Please give information on the format and availability of data stored in a database (3)**

Database on spreadsheet (e.g. excel)

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (4)**

No

**% available**

**Other (please specify)**

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (1)**

Data is held as individual records

**% available**

100

**Q13b. Please give information on the format and availability of data held as individual records (2)**

No

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (3)**

Data held on computer based records

**% available**

100

**Q13b. Please give information on the format and availability of data held as individual records (4)**

No

**% available**

**Please specify language used**

English

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Apply to PI or co-ordinator at resource| Access committee mechanism

**Q15. What data sharing policy is specified as a condition of use?**

No requirement to make data publicly available

**Q16a. Are tissues/samples/DNA available to other groups?**

No

**Q16b i) If yes, please describe below:**

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

**Q17. Is information on biological characteristics available to other groups?**

Yes, for all the cohort

**Number of Patients**

**% of total cohort**

**Types:**

Population Cohorts

**Member States:**

Australia

**Diseases:**

Neurodegenerative disease in general

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A